IQVIA Holdings Inc (IQV)vsVale SA ADR (VALE)
IQV
IQVIA Holdings Inc
$165.64
-0.27%
HEALTHCARE · Cap: $28.11B
VALE
Vale SA ADR
$15.14
+1.82%
BASIC MATERIALS · Cap: $64.24B
Smart Verdict
WallStSmart Research — data-driven comparison
Vale SA ADR generates 1210% more annual revenue ($213.59B vs $16.31B). IQV leads profitability with a 8.3% profit margin vs 6.5%. IQV appears more attractively valued with a PEG of 0.97. IQV earns a higher WallStSmart Score of 72/100 (B).
IQV
Strong Buy72
out of 100
Grade: B
VALE
Buy55
out of 100
Grade: C
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+49.1%
Fair Value
$348.46
Current Price
$165.64
$182.82 discount
Margin of Safety
-47.9%
Fair Value
$11.75
Current Price
$15.14
$3.39 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Every $100 of equity generates 21 in profit
Growing faster than its price suggests
Earnings expanding 23.6% YoY
Large-cap with strong market position
Reasonable price relative to book value
Strong operational efficiency at 27.6%
Areas to Watch
Distress zone — elevated risk
Moderate valuation
0.5% revenue growth
ROE of 5.9% — below average capital efficiency
6.5% margin — thin
Comparative Analysis Report
WallStSmart ResearchBull Case : IQV
The strongest argument for IQV centers on Return on Equity, PEG Ratio, EPS Growth. Revenue growth of 10.3% demonstrates continued momentum. PEG of 0.97 suggests the stock is reasonably priced for its growth.
Bull Case : VALE
The strongest argument for VALE centers on Market Cap, Price/Book, Operating Margin.
Bear Case : IQV
The primary concerns for IQV are Altman Z-Score.
Bear Case : VALE
The primary concerns for VALE are P/E Ratio, Revenue Growth, Return on Equity.
Key Dynamics to Monitor
IQV carries more volatility with a beta of 1.41 — expect wider price swings.
IQV is growing revenue faster at 10.3% — sustainability is the question.
VALE generates stronger free cash flow (723M), providing more financial flexibility.
Monitor DIAGNOSTICS & RESEARCH industry trends, competitive dynamics, and regulatory changes.
Bottom Line
IQV scores higher overall (72/100 vs 55/100) and 10.3% revenue growth. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
IQVIA Holdings Inc
HEALTHCARE · DIAGNOSTICS & RESEARCH · USA
IQVIA, formerly Quintiles and IMS Health, Inc., is an American multinational company serving the combined industries of health information technology and clinical research. It is a provider of biopharmaceutical development and commercial outsourcing services, focused primarily on Phase I-IV clinical trials and associated laboratory and analytical services, including consulting services.
Vale SA ADR
BASIC MATERIALS · OTHER INDUSTRIAL METALS & MINING · USA
Vale SA produces and sells iron ore and iron ore pellets for use as raw material in steelmaking in Brazil and internationally. The company is headquartered in Rio de Janeiro, Brazil.
Compare with Other DIAGNOSTICS & RESEARCH Stocks
Want to dig deeper into these stocks?